Characterization of α1‐adrenoceptor subtypes in tension response of human prostate to electrical field stimulation

1 The effects of various α1‐adrenoceptor antagonists and nifedipine on tension responses of human prostate to electrical field stimulation were evaluated in this study. 2 Prazosin (3 × 10−10 to 10−8M) and 5‐methyl‐urapidil (10−9 to 3 × 10−8 M) blocked concentration‐dependently the tension responses to electrical field stimulation and completely abolished them in the maximal concentrations (10−8 M and 3 × 10−8 M, respectively); in contrast, chloroethylclonidine (CEC), in the maximal concentration of 100 μM, blocked these effects by only 50%. 3 The contractile responses of rat vas deferens and spleen to exogenously‐applied α1radrenoceptor agonists were competitively inhibited by prazosin and 5‐methyl‐urapidil; in addition, the pA2 values were calculated and the relative potencies with reference to prazosin were obtained. The relative potency of 5‐methyl‐urapidil in human prostate (0.105) was close to that in rat vas deferens (0.257), which contains primarily putative α1A‐adrenoceptors. However, it was much more than that in rat spleen (0.011), which contains primarily putative α1B‐adrenoceptors. 4 Nifedipine (10−8 to 10−6 M) inhibited concentration‐dependently the contractile responses to electrical field stimulation in human prostate; in addition, the inhibition percentages were similar to those to exogenously‐applied noradrenaline in rat vas deferens. In contrast, CEC (10 μM), which almost flattened the concentration‐response curve of the rat spleen to phenylephrine, only partially inhibited (by 33.1%) the nerve‐mediated contraction of human prostate. 5 The involvement of prejunctional α2‐adrenoceptors situated on the sympathetic nerve terminals of human prostate was also examined. Clonidine (3 × 10−9 to 3 × 10−7 M) blocked concentration‐dependently the contractile response to electrical field stimulation of human prostate and this inhibitory effect was reversed by yohimbine (10−7 M). Additionally, the inhibitory effect of CEC (3 × 10−6 to 3 × 10−4 M) to the nerve‐mediated contraction was also partially reversed by yohimbine (10−7M). 6 It is suggested that the putative α1A‐adrenoceptors in human prostate may be functionally confined to the synaptic region whereas only minor populations of the putative α1B‐ and/or αlc‐adrenoceptors exist in this region.

[1]  M. Wyllie,et al.  Pharmacological properties of the cloned α1A/D‐adrenoceptor subtype are consistent with the α1A‐adrenoceptor characterized in rat cerebral cortex and vas deferens , 1994 .

[2]  T. Branchek,et al.  Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. , 1993, Molecular pharmacology.

[3]  G. Strada,et al.  Characterization of α1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man , 1993 .

[4]  M. Caron,et al.  Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. , 1993, The Journal of urology.

[5]  J. Docherty,et al.  Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. , 1993, British journal of pharmacology.

[6]  H. Lepor,et al.  Alpha 1 adrenoceptor subtypes in the human prostate. , 1993, The Journal of urology.

[7]  J. Lomasney,et al.  Pharmacologic characterization of cloned alpha 1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype. , 1992, European journal of pharmacology.

[8]  M. Macías-Silva,et al.  Species heterogeneity of hepatic ?1-adrenoceptors: ?1A-, ?1B- and ?1C-subtypes , 1992 .

[9]  T. Philipp,et al.  α‐ and β‐Adrenoceptors in Hypertension: Molecular Biology and Pharmacological Studies , 1992 .

[10]  M. Caron,et al.  The alpha 1C-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. , 1991, Molecular pharmacology.

[11]  H. Bensadoun,et al.  Alfuzosin for treatment of benign prostatic hypertrophy , 1991, The Lancet.

[12]  M. Caron,et al.  Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5. , 1991, The Journal of biological chemistry.

[13]  K. Minneman,et al.  Subtypes of α1adrenoceptors in rat blood vessels , 1990 .

[14]  G. Burnstock,et al.  Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. , 1989, The Journal of urology.

[15]  G. Gross,et al.  Subclassification of α1‐adrenoceptor recognition sites by urapidil derivatives and other selective antagonists , 1989, British journal of pharmacology.

[16]  M. Caron,et al.  Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Gross,et al.  5-Methyl-urapidil discriminates between subtypes of the α1-adrenoceptor , 1988 .

[18]  K. Minneman Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+. , 1988, Pharmacological reviews.

[19]  P. Abel,et al.  Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101. , 1988, Molecular pharmacology.

[20]  T. Kenakin,et al.  Classification of phenoxybenzamine/prazosin-resistant contractions of rat spleen to norepinephrine by Schild analysis: similarities and differences to postsynaptic alpha-2 adrenoceptors. , 1988, The Journal of pharmacology and experimental therapeutics.

[21]  R. Kirby,et al.  Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. , 1987, British journal of urology.

[22]  J. Kumazawa,et al.  Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. , 1987, The Journal of urology.

[23]  S. Yamada,et al.  Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. , 1987, The Journal of pharmacology and experimental therapeutics.

[24]  P. Abel,et al.  α1Adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle , 1987, Nature.

[25]  M. Caine Clinical experience with alpha-adrenoceptor antagonists in benign prostatic hypertrophy. , 1986, Federation proceedings.

[26]  K. Andersson,et al.  Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. , 1985, The Journal of urology.

[27]  D. Triggle,et al.  Calcium channel antagonists: pharmacological considerations. , 1985, British journal of clinical pharmacology.

[28]  J. Hieble,et al.  In vitro characterization of the alpha-adrenoceptors in human prostate. , 1985, European journal of pharmacology.

[29]  S. Meretyk,et al.  A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. , 1978, British journal of urology.

[30]  D. Mackay How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? , 1978, The Journal of pharmacy and pharmacology.

[31]  H. Schild,et al.  SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.